The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Therefore, antibodies targeting PD-1 receptor or PD-L1 are being investigated [225].”
BackgroundFOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“Furthermore, recent analysis of gene expression and activity allowed for classification of observed mutations into four distinct phenotypic subtypes defined as squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX) [4].”
BackgroundChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Maitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells
Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., Ramm, G. A., Buchler, M., Friess, H., McCarroll, J. A., et al. (2004) · Pancreas · doi:10.1097/00006676-200410000-00002 · Cited by 591
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343 · cited 1×
“The most frequent among them are KRAS alterations (85%), which mainly consist of substitution of G12, resulting in a constitutively active protein [141].”
Background
Cited by
Lazzari, G., Nicolas, V., Matsusaki, M., Akashi, M., Couvreur, P., & Mura, S. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.08.008 · Cited by 271
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
Poh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106
USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation
Hou, P., Ma, X., Zhang, Q., Wu, C.-J., Liao, W., Li, J., Wang, H., Zhao, J., Zhou, X., Guan, C., et al. (2019) · Genes & Development · doi:10.1101/gad.326314.119 · Cited by 96
Qureshi, T. A., Gaddam, S., Wachsman, A. M., Wang, L., Azab, L., Asadpour, V., Chen, W., Xie, Y., Wu, B., Pandol, S. J., et al. (2022) · Cancer Biomarkers · doi:10.3233/cbm-210273 · Cited by 79
Vonderhaar, E. P., Barnekow, N. S., McAllister, D., McOlash, L., Eid, M. A., Riese, M. J., Tarakanova, V. L., Johnson, B. D., & Dwinell, M. B. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.018 · Cited by 61
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice
Kishimoto, S., Brender, J. R., Crooks, D. R., Matsumoto, S., Seki, T., Oshima, N., Merkle, H., Lin, P., Reed, G., Chen, A. P., et al. (2019) · eLife · doi:10.7554/elife.46312 · Cited by 41
“Given PDACs resistance to traditional chemo- and radiotherapy regimes (Adamska et al., 2017), alternative points of attack are being considered.”
BackgroundDe Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
A 3D pancreatic tumor model to study T cell infiltration
Mollica, H., Teo, Y. J., Tan, A. S. M., Tan, D. Z. M., Decuzzi, P., Pavesi, A., & Adriani, G. (2021) · Biomaterials Science · doi:10.1039/d1bm00210d · Cited by 32
MicroRNAs Targeting Caspase-3 and -7 in PANC-1 Cells
Park, J. K., Doseff, A. I., & Schmittgen, T. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041206 · Cited by 27
Pancreatic Adenocarcinoma: Imaging Modalities and the Role of Artificial Intelligence
Anghel, C., Mugur, G. C., Anghel, D. A., Rusu-Munteanu, G. I., Dumitru, R. L., & Lupescu, I. G. (2024) · doi:10.20944/preprints202401.0904.v1 · Cited by 23
Liang, L., Ding, Y., Yu, Y., Liu, K., Rao, S., Ge, Y., & Zeng, M. (2021) · BMC Medical Imaging · doi:10.1186/s12880-021-00605-4 · Cited by 13
Metadata
- Authors
- Adamska, A., Domenichini, A., & Falasca, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-06-22
- Volume
- 18
- Issue
- 7
- Pages
- 1338
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2683486796
- Cited by
- 610
- References
- 16
- FWCI
- 21.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
